File Download
There are no files associated with this item.
Links for fulltext
(May Require Subscription)
- Publisher Website: 10.1016/S0168-8278(18)31241-8
- WOS: WOS:000461068602208
- Find via
Supplementary
-
Citations:
- Web of Science: 0
- Appears in Collections:
Conference Paper: Serum Mac-2-binding protein glycosylation isomer in assessing liver fibrosis in chronic hepatitis B infection
Title | Serum Mac-2-binding protein glycosylation isomer in assessing liver fibrosis in chronic hepatitis B infection |
---|---|
Authors | |
Issue Date | 2018 |
Publisher | Elsevier BV. The Journal's web site is located at http://www.elsevier.com/locate/jhep |
Citation | The International Liver Congress 2018 (ILC 2018), Paris, France, 11–15 April 2018. Abstract Book in Journal of Hepatology, 2018, v. 68 n. Suppl. 1, p. S496, abstract no. FRI-301 How to Cite? |
Abstract | Background and Aims: Mac-2-binding protein glycosylation isomer (M2BPGi) is a novel serum marker for diagnosis of liver fibrosis in various liver diseases, while data in chronic hepatitis B (CHB), especially longitudinal data, is limited.We aimed to evaluate the role of M2BPGi in diagnosing advanced fibrosis (F3) and cirrhosis (F4) in HBeAg-ve CHB using liver stiffness measurement (LSM) as the reference.
Method: We performed transient elastography for HBeAg-ve CHB patients who were managed in Queen Mary Hospital, Hong Kong. LSM was performed by Fibroscan® (Echosens, Paris, France) and
presence of no/minimal fibrosis (F0/F1), grey area and F3/F4 was defined using the alanine-aminotransferase-based EASL-ALEH criteria. Serum M2BPGi were measured using the HISCL-800 immunoanalyzer (Sysmex Corporation, Hyogo, Japan).
Results: 240 HBeAg-ve CHB patients (M:F = 116:124) of median age 47.5 years were recruited. The majority were treatment-experienced (85.8%). The median ALT was 26 U/l (range: 10–180 U/l). The median liver stiffness was 6.9 kPa (IQR 4.9–11.7 kPa) and 78 of them (32.5%) had F3/F4 by transient elastography at baseline. The corresponding median M2BPGi values for F0/1/2, F3 and F4 progressively increased in parallel with more advanced stages of liver fibrosis: 0.39, 0.46 and 0.82 COI, respectively (p < 0.01) (Figure 1A). The AUROC for diagnosing ≥ F3 by serum M2BPGi was 0.754. Using a cut-off value of 0.605, the sensitivity, specificity, PPV and NPV for ≥ F3 was 62.5%, 79.4%, 60.3% and 80.9%, respectively. In a subgroup of 86 patients who had repeated LSM 10 years after the initial LSM, the proportion of patients with F3/4 was reduced from 36.7% to 16.3% (p < 0.001). The median serum M2BPGi levels were significantly different between patients with F3/4 compared to those with F0/1/2 at
baseline (0.67 COI vs. 0.41 COI, p < 0.05) and also at 10-year (0.62 COI vs. 0.48 COI, p = 0.039). 21 (24.4%) showed significant fibrosis regression (i.e. F3 or F4 → F0 or F1). The median change in serum
M2BPGi level was -0.11 compared to + 0.03 COI in the other patients who did not showed significant fibrosis regression (p = 0.011). (Figures 1C-1D)
Conclusion: Serum M2BPGi was an accurate serum marker for liver fibrosis in HBeAg-ve CHB patients. Using a cut-off level of 0.605 COI, 80.9% patients without ≥ F3 can be excluded. Serum M2BPGi levels
remained significantly higher for patients with ≥ F3 compared to those with F0/1/2 even after 10 years. Serum M2BPGi levels also decreased significantly in patients who had fibrosis regression after 10 years. |
Description | Poster Presentation - no. FRI-301 The Congress was hosted by The European Association for the Study of the Liver (EASL) |
Persistent Identifier | http://hdl.handle.net/10722/262207 |
ISSN | 2023 Impact Factor: 26.8 2023 SCImago Journal Rankings: 9.857 |
ISI Accession Number ID |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Mak, LY | - |
dc.contributor.author | Seto, WKW | - |
dc.contributor.author | Cheung, KSM | - |
dc.contributor.author | Fung, JYY | - |
dc.contributor.author | Wong, DKH | - |
dc.contributor.author | Lai, CL | - |
dc.contributor.author | Yuen, RMF | - |
dc.date.accessioned | 2018-09-28T04:55:12Z | - |
dc.date.available | 2018-09-28T04:55:12Z | - |
dc.date.issued | 2018 | - |
dc.identifier.citation | The International Liver Congress 2018 (ILC 2018), Paris, France, 11–15 April 2018. Abstract Book in Journal of Hepatology, 2018, v. 68 n. Suppl. 1, p. S496, abstract no. FRI-301 | - |
dc.identifier.issn | 0168-8278 | - |
dc.identifier.uri | http://hdl.handle.net/10722/262207 | - |
dc.description | Poster Presentation - no. FRI-301 | - |
dc.description | The Congress was hosted by The European Association for the Study of the Liver (EASL) | - |
dc.description.abstract | Background and Aims: Mac-2-binding protein glycosylation isomer (M2BPGi) is a novel serum marker for diagnosis of liver fibrosis in various liver diseases, while data in chronic hepatitis B (CHB), especially longitudinal data, is limited.We aimed to evaluate the role of M2BPGi in diagnosing advanced fibrosis (F3) and cirrhosis (F4) in HBeAg-ve CHB using liver stiffness measurement (LSM) as the reference. Method: We performed transient elastography for HBeAg-ve CHB patients who were managed in Queen Mary Hospital, Hong Kong. LSM was performed by Fibroscan® (Echosens, Paris, France) and presence of no/minimal fibrosis (F0/F1), grey area and F3/F4 was defined using the alanine-aminotransferase-based EASL-ALEH criteria. Serum M2BPGi were measured using the HISCL-800 immunoanalyzer (Sysmex Corporation, Hyogo, Japan). Results: 240 HBeAg-ve CHB patients (M:F = 116:124) of median age 47.5 years were recruited. The majority were treatment-experienced (85.8%). The median ALT was 26 U/l (range: 10–180 U/l). The median liver stiffness was 6.9 kPa (IQR 4.9–11.7 kPa) and 78 of them (32.5%) had F3/F4 by transient elastography at baseline. The corresponding median M2BPGi values for F0/1/2, F3 and F4 progressively increased in parallel with more advanced stages of liver fibrosis: 0.39, 0.46 and 0.82 COI, respectively (p < 0.01) (Figure 1A). The AUROC for diagnosing ≥ F3 by serum M2BPGi was 0.754. Using a cut-off value of 0.605, the sensitivity, specificity, PPV and NPV for ≥ F3 was 62.5%, 79.4%, 60.3% and 80.9%, respectively. In a subgroup of 86 patients who had repeated LSM 10 years after the initial LSM, the proportion of patients with F3/4 was reduced from 36.7% to 16.3% (p < 0.001). The median serum M2BPGi levels were significantly different between patients with F3/4 compared to those with F0/1/2 at baseline (0.67 COI vs. 0.41 COI, p < 0.05) and also at 10-year (0.62 COI vs. 0.48 COI, p = 0.039). 21 (24.4%) showed significant fibrosis regression (i.e. F3 or F4 → F0 or F1). The median change in serum M2BPGi level was -0.11 compared to + 0.03 COI in the other patients who did not showed significant fibrosis regression (p = 0.011). (Figures 1C-1D) Conclusion: Serum M2BPGi was an accurate serum marker for liver fibrosis in HBeAg-ve CHB patients. Using a cut-off level of 0.605 COI, 80.9% patients without ≥ F3 can be excluded. Serum M2BPGi levels remained significantly higher for patients with ≥ F3 compared to those with F0/1/2 even after 10 years. Serum M2BPGi levels also decreased significantly in patients who had fibrosis regression after 10 years. | - |
dc.language | eng | - |
dc.publisher | Elsevier BV. The Journal's web site is located at http://www.elsevier.com/locate/jhep | - |
dc.relation.ispartof | Journal of Hepatology | - |
dc.relation.ispartof | The International Liver Congress 2018 (ILC 2018) | - |
dc.title | Serum Mac-2-binding protein glycosylation isomer in assessing liver fibrosis in chronic hepatitis B infection | - |
dc.type | Conference_Paper | - |
dc.identifier.email | Seto, WKW: wkseto@hku.hk | - |
dc.identifier.email | Cheung, KSM: cks634@hku.hk | - |
dc.identifier.email | Fung, JYY: jfung@hkucc.hku.hk | - |
dc.identifier.email | Wong, DKH: danywong@hku.hk | - |
dc.identifier.email | Lai, CL: hrmelcl@hkucc.hku.hk | - |
dc.identifier.email | Yuen, RMF: mfyuen@hku.hk | - |
dc.identifier.authority | Seto, WKW=rp01659 | - |
dc.identifier.authority | Fung, JYY=rp00518 | - |
dc.identifier.authority | Wong, DKH=rp00492 | - |
dc.identifier.authority | Lai, CL=rp00314 | - |
dc.identifier.authority | Yuen, RMF=rp00479 | - |
dc.description.nature | link_to_subscribed_fulltext | - |
dc.identifier.doi | 10.1016/S0168-8278(18)31241-8 | - |
dc.identifier.hkuros | 292249 | - |
dc.identifier.volume | 68 | - |
dc.identifier.issue | Suppl. 1 | - |
dc.identifier.spage | S496, abstract no. FRI-301 | - |
dc.identifier.epage | S496, abstract no. FRI-301 | - |
dc.identifier.isi | WOS:000461068602208 | - |
dc.publisher.place | Netherlands | - |
dc.identifier.issnl | 0168-8278 | - |